Lilly Says Retatrutide More Than Doubles Ozempic Weight Loss in Trial

Eli Lilly (LLY) was on investors’ radar on Wednesday after the pharmaceutical behemoth said its experimental diabetes and obesity drug, Retatrutide, delivered more than double the weight loss of Novo Nordisk’s (NVO) Ozempic in a head-to-head trial, intensifying the rivalry to capture the fast-growi…